Mark Altmeyer, MBA
Mark Altmeyer is a senior advisor for Orange Grove Bio ("OGB"). He was most recently the Founder and Chief Executive Officer of Arvelle Therapeutics. Arvelle was acquired by Angelini Pharma in Feb 2021. He has 35+ years of experience leading successful drug development and commercialization efforts as a pharmaceutical executive. He has broad therapeutic expertise having worked across multiple different therapeutic classes (Diabetes, Cardiovascular, anti-infectives) with a focus on central nervous system (CNS) disorders and oncology. He was previously President and Chief Commercial Officer at Axovant Sciences.
Prior to that Mark was Chief Executive Officer and President of Otsuka America Pharmaceutical, Inc., where he led a team of 1,700 employees and helped grow the company’s revenue from $2.6 billion to over $5 billion. He led the launch of Abilify®, the top-selling CNS drug in history and the number-one selling drug in the United States in 2013. Earlier in his career, Mr. Altmeyer held a number of executive leadership roles at Bristol-Myers Squibb, including Senior Vice President, Global Commercialization, and Senior Vice President, Neuroscience Business Unit. Mr. Altmeyer received an M.B.A. from Harvard Business School and a B.A. in economics from Middlebury College.